Navigation Links
Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care

mall group of women with endometriosis, they are reflective of six months of treatment, and we are pleased that the data from the three-month interim analysis have been confirmed. This study has been significant in indicating that there is a relationship between dose, duration of therapy, the risk of endometrial thickening and potential for unusual endometrial bleeding. In studying these relationships Repros has formulated a strategy to successfully manage this by adjusting treatment cycles to four months, and to use a 50mg dose that is associated with a lesser tendency to endometrial thickening with time. Each treatment cycle will be followed by a drug holiday in order to refresh the endometrium. After the occurrence of normal menstruation, a new four-month treatment cycle will be started. In this way the symptoms of endometriosis could be controlled in the long term without the occurrence of unscheduled bleeding. This treatment strategy was discussed with the FDA at our March Pre-IND meeting and all future studies with Proellex will be conducted in this way."

Joseph Podolski, President and CEO of Repros, added, "The endometriosis market is large and remains under-served and represents a significant unmet need in women's health. Few drug therapies are viable for long-term use, leaving invasive laparoscopy as the most common treatment. We strongly believe that Proellex, with the efficacy and safety it is demonstrating here, has the potential to become an important medical approach to the long-term treatment of this difficult to manage condition."

Repros met with the FDA at a Pre-IND meeting in March and will be submitting an IND for the treatment of endometriosis this summer. Repros plans to commence a U.S. Phase 2 clinical trial before year end, pending approval of the IND.

About Repros Therapeutics Inc.

Repros is engaged in the development of pharmaceutical products that address conditions of the male and female reproductive systems. Pr
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:7/31/2015)...  Boston Children,s Hospital physicians report the first ... their anatomy before undergoing high-risk brain procedures. The ... the brain,s blood vessels) that posed special treatment ... Journal of Neurosurgery: Pediatrics , the physicians ... resins to create custom, high-fidelity models of the ...
(Date:7/31/2015)... 31, 2015  Xcelience, a contract development and ... made a structured cash investment in Powdersize, a ... milling, micronization and powder size classification within the ... business while simultaneously adding a complete set of ... capabilities. "As we continue to ...
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
Breaking Medicine Technology:3D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 will emanate ... Football League’s biggest day each year is the Super Bowl. In the two weeks that ... place from the host venue. The 2016 Super Bowl game will mark the 50th time ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage ... also the first provider of Exilis non-surgical fat reduction in New York. Due ... attracted a large International clientele. Many patients travel to New York to get ...
(Date:7/31/2015)... Alexandria, VA (PRWEB) , ... July 31, 2015 ... ... Foundation) introduced its new store run by GoodThreads. The store can be accessed ... products and designs, many of which are customizable. The best part: whenever a ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Sculpted Contours Luxury ... CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in the United ... 2014 for treating the outer thighs. The original applicator required a 2 hour ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... Australia, April 20 Progen Pharmaceuticals Limited (ASX: PGL; ... that shows its epigenetic technology successfully inhibits tumor ... Progen,s collaborators at the 100th Annual American Association ... was effective in ,switching on, important anti-cancer genes ...
... with the power and influence to improve the healthcare ... to reform the nation,s healthcare system dominate Modern ... Healthcare for 2009. Among those making the list are ... Services Department; Nancy-Ann DeParle, director of the newly created ...
... - A national team of researchers led by Mayo Clinic ... more likely to have similar DNA changes or variants in ... have the cancer. , The findings, being presented at the ... an independent validation of an earlier European study that found ...
... Southern California have identified a new drug compound that ... without the negative side effects typically associated with Cox-2 ... to have a strong anti-tumor effect while also attacking ... tumor growth, according to data presented at the AACR ...
... Universal Health Realty Income Trust (NYSE: UHT ) ... C. Stein as a Trustee. Mr. Stein becomes the seventh ... Trustee. Mr. Stein, 50, is currently president and ... real estate company specializing in the acquisition, development, leasing and ...
... to Provide Free Counseling to Military Members, Veterans, and ... is honoring National Volunteer Week (April 19-25, 2009) with ... professionals to join the Give an Hour(TM) network to ... Hour(TM) is a nonprofit organization that has created a ...
Cached Medicine News:Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 2Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 3Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 4Health News:Health Reformers Dominate Magazine's List of the Top 25 Women in Healthcare 2Health News:Mayo Clinic-led researchers confirm gene variants associated with the most common adult leukemia 2Health News:USC researchers develop new drug to target tumor cells and blood vessels 2Health News:Give an Hour(TM) Honors National Volunteer Week with Call to Service 2
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 25G x 5/8in (.50 x 16mm)...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. Two 25G (.50mm) parallel ...
... product designed for LASIK surgery and ... to irrigate the corneal interface and/or ... insertion under the flap and helps ... provide multi-directional irrigation. 25G x 7/8in ...
Cannula tip is specially rounded, extra smooth for safe insertion through wound and manipulation in the anterior chamber. 23G x 7/8 in (.60 x 22mm). .3mm end port. Olive shape tip is 2mm long x 1mm w...
Medicine Products: